Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth

Fig. 5

In vivo antitumoural effect of CD::UPRT::GFP_AD-MSCs in the presence of 5FC. To establish s.c tumour, 5 × 106 U-251MG™ZR40cells were injected subcutaneously in dorsal flank regions. When tumour reached the target size, CD::UPRT::GFP_AD-MSCs or AD-MSCs were injected directly to the s.c. tumour. One day later, 500 mg/kg/day of 5FC was administered intraperitoneally for 4 consecutive days. The size of s.c tumour was measured with a vernier calliper up to 15 days post-AD-MSC administration. The group that received unmodified AD-MSCs/5FC serves as the control group. Tumour volume (mm3) was calculated according to the standard formula of V = (W × W × L)/2. a The line graph displays the tumour size in the three groups over time measured from n = 6 from each group. Data is presented as mean + SD, n = 6. b At the end of the study, the tumours were extracted for weight measurement. Graph bar demonstrates the average of tumour weight for each group. Data were expressed as mean + SD, n = 6. Significant differences between the three groups were calculated using two-tailed Student’s t test. *P < 0.05, n.s indicates statistical insignificance between groups. c The weight of the mice was measured at each time point prior to measurement of the tumour volume. The percentage of change in weight was defined as weight/weight before AD-MSC administration × 100%. The line graph displays average of the percentage in weight change + SD of 6 mice in each group

Back to article page